President Trump said nine more drugmakers joined his “most favored nation” pricing push, a move the White House says now covers about 89 percent of the branded market.
Story Snapshot
- Nine additional companies signed on, bringing total participants to 26.
- The policy ties U.S. prices to the lowest paid in comparable wealthy nations.
- The White House projects more than $600 billion in savings over a decade.
- New deals touch drugs for cancer, Parkinson’s, glaucoma, and more.
What Changed With The New Round Of Company Deals
On August 31, the White House announced agreements with nine more drugmakers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These add to 17 earlier deals, bringing the total to 26 companies. The administration says this expands coverage to roughly 89 percent of the branded drug market. The move builds on earlier steps this year, which set the basic framework for pricing and participation.
The announcement follows months of outreach to large manufacturers. Earlier public statements and company notices signaled that many firms had already accepted the structure. Those reports included references to incentives, like tariff flexibility and new direct-to-consumer options, suggesting the policy uses both pressure and access to win buy-in. The August 31 update appears to be an incremental but significant expansion of that foundation, not a brand-new program.
How The Most Favored Nation Pricing Is Supposed To Work
The policy links the price Americans pay for covered brand-name drugs to the lowest prices paid in comparable developed countries. The White House frames this as a fairness test: patients here should not pay more than patients abroad for the same medicine. The approach relies on negotiated agreements with manufacturers and aims to translate those benchmarks into what people actually pay at the counter or through their plan benefits.
President Trump and his team say this shift will deliver very large savings over time. The administration has spotlighted examples and issued a savings outline, and the President has cited a figure of more than $600 billion over ten years. That number is a projection from the White House; the public materials do not include a full actuarial model that shows the underlying math. Still, it captures the scale of the administration’s goal.
Which Medicines And Patients Could Feel It First
Coverage of the announcement highlighted drugs for serious and common conditions. Reporters pointed to therapies for hemophilia, Parkinson’s disease, glaucoma, liver disease, several cancers, transplants, and infectious diseases. Those areas suggest impact across both specialty and chronic care. Earlier updates also flagged price points for popular diabetes and weight-loss medicines in Medicare, indicating that some headline therapies already have documented benchmarks within the broader effort.
President Donald Trump announced an expansion of his Most Favored Nation drug pricing initiative on Monday afternoon from the White House.https://t.co/44gRCb9yUj
— ABC 13 News – WSET (@ABC13News) September 1, 2026
Patients, employers, and plans will watch how quickly list prices, net prices after rebates, and out-of-pocket costs move. The plan’s promise depends on how negotiated reference prices flow through insurers, pharmacies, and benefit designs. Some earlier reports noted that a few company agreements may last about three years, which means renewals and continued participation will matter if leaders want multi-year savings to hold beyond the first term of these deals.
Why This Push Matters Beyond Today’s Headlines
Drug prices have strained family budgets for years. Americans often pay more than people in other rich countries for the same brands. That has fed anger on both the right and the left, who see a system that too often favors the well-connected. A policy that ties prices here to the lowest abroad speaks to that frustration. It claims to use the market power of the United States to demand a better deal and to deliver relief without asking patients to jump through new hoops.
Supporters say the expansion shows leverage is working across most of the branded market. They argue that broad participation can speed up real savings because companies will not want to be the outlier. The administration underscores that this strategy aims to protect access while cutting costs. As with any major change, execution will decide the results. Patients will judge success by what they pay at the pharmacy, not by sign-up counts or press releases.
Sources:
washingtontimes.com, whitehouse.gov, npr.org, amcp.org, statnews.com, thegatewaypundit.com, ispor.org